Regenerative medicine firm Humacyte lands $12M, CEO Carrie Cox
Duke University spin-off Humacyte Inc. has landed a $12 million investment and a new CEO: pharmaceutical industry veteran Carrie Cox. The former executive vice president and president of Global Pharmaceuticals at Schering-Plough Corp. left that company with a golden parachute estimated at between $36 million and $44 million when it was acquired by Merck & Co. in November.